Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16267716 | 0.88 | PNMT (0.53) | PNMTADRA2A | |
| SCHEMBL29652240 | 0.88 | PNMT (0.53) | PNMTADRA2A | |
| SCHEMBL21489595 | 0.88 | PNMT (0.53) | PNMTADRA2A | |
| SCHEMBL21496903 | 0.81 | PNMT (0.44) | PNMTADRA2A | |
| SCHEMBL25251593 | 0.81 | ABHD6 (0.36) | PNMTKDM1A | |
| Trifluoroacetic Acid SCHEMBL383916 | 0.76 | ABHD6 (0.40) | PNMTKDM1A | |
| SCHEMBL31651974 | 0.73 | EGLN1 (0.43) | — | |
| SCHEMBL16268692 | 0.73 | EGLN1 (0.43) | — | |
| SCHEMBL30543100 | 0.73 | EGLN1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL32676919 | 0.72 | EGLN1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4200280-B1 | PHENYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | LILLY CO ELI (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20230382869-A1 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | ELI LILLY AND COMPANY | 2023-11-30 | — | — | US | disclosed |
| EP-4200280-A1 | PHENYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL-ETHAN-1-ONE DERIVATIVES AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | ELI LILLY AND COMPANY (US) | 2023-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382869-A1 | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators | HTR1D, ADRA1D, HTR1A | PNMT 173/4885KDM1A 1087/4885ADRA2A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.